Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

This study has been terminated.
(Only 2 patients screened but none of them were enrolled.)
Information provided by (Responsible Party):
Hoffmann-La Roche Identifier:
First received: March 11, 2013
Last updated: September 2, 2016
Last verified: September 2016
This clinical study is to determine if the use of structured testing, which is a blood glucose monitoring, via the Accu-Chek 360° View blood glucose analysis tool has a positive effect on the subjects overall glycemic control.

Condition Intervention
Device: ;Accu-Chek Compact Plus LCM bulk Japan

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Diagnostic
Official Title: Study on Improvement of Blood Glucose Control in Patients With Diabetes Type 2 Using SMBG

Resource links provided by NLM:

Further study details as provided by Hoffmann-La Roche:

Primary Outcome Measures:
  • Improvement in HbA1c in 6 months [ Time Frame: 6 months ]

Secondary Outcome Measures:
  • 1. Comparison with historical control in HbA1c change. [ Time Frame: Baseline to 6 months ]
  • 2. Change in blood gulucose. [ Time Frame: Baseline to 6 months ]
  • 3. Change in BMI. [ Time Frame: Baseline to 6 months ]
  • 4. Occurance of sever hypoglycemia. [ Time Frame: Baseline to 6 months ]
  • 5. Doctor's opinion for Accu-Chek 360° View. [ Time Frame: Baseline to 6 months ]

Enrollment: 2
Study Start Date: April 2013
Study Completion Date: December 2013
Primary Completion Date: December 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Single arm Device: ;Accu-Chek Compact Plus LCM bulk Japan
HbA1c would be changed by more careful control in blood glucose with SMBG.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All

Inclusion Criteria:

1. Age:= and >20 years. 2. Intend to paticipate in this study after education of structured testing. 3.HbA1c:= and >7.5% in the recect 2 months.

Exclusion Criteria:

1.Pregancy. 2. Heavy complication 3. judged unsuitable by doctor

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01820169

Kyoto, Japan, 612-8555
Sponsors and Collaborators
Hoffmann-La Roche
Principal Investigator: Naoki Sakane National organization Hospital Kyoto Medical Center
  More Information

Responsible Party: Hoffmann-La Roche Identifier: NCT01820169     History of Changes
Other Study ID Numbers: RD001551
Study First Received: March 11, 2013
Last Updated: September 2, 2016

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases processed this record on May 25, 2017